197 related articles for article (PubMed ID: 19020111)
1. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains.
Fazekas G; Martosne-Mendi R; Jankovics I; Szilvasy I; Vajo Z
Clin Vaccine Immunol; 2009 Apr; 16(4):437-43. PubMed ID: 19020111
[TBL] [Abstract][Full Text] [Related]
2. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
3. Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.
Forrest HL; Khalenkov AM; Govorkova EA; Kim JK; Del Giudice G; Webster RG
Vaccine; 2009 Jun; 27(31):4187-95. PubMed ID: 19406182
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
Chada KE; Forshee R; Golding H; Anderson S; Yang H
Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
[TBL] [Abstract][Full Text] [Related]
5. Yearly licensing studies from 1997 to 2007 of the inactivated whole virus seasonal influenza vaccine fluval--a useful approach to pandemic vaccine development even in less well developed countries?
Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Jankovics M; Kis A; Jankovics I
Influenza Other Respir Viruses; 2008 Nov; 2(6):221-8. PubMed ID: 19453398
[TBL] [Abstract][Full Text] [Related]
6. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
8. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
[TBL] [Abstract][Full Text] [Related]
9. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
Carter NJ; Plosker GL
BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
[TBL] [Abstract][Full Text] [Related]
10. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
11. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
[TBL] [Abstract][Full Text] [Related]
12. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
13. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
15. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
17. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
18. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
19. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Sansyzbay AR; Erofeeva MK; Khairullin BM; Sandybayev NT; Kydyrbayev ZK; Mamadaliyev SM; Kassenov MM; Sergeeva MV; Romanova JR; Krivitskaya VZ; Kiselev OI; Stukova MA
Clin Vaccine Immunol; 2013 Aug; 20(8):1314-9. PubMed ID: 23803900
[TBL] [Abstract][Full Text] [Related]
20. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.
Leroux-Roels I; Bernhard R; Gérard P; Dramé M; Hanon E; Leroux-Roels G
PLoS One; 2008 Feb; 3(2):e1665. PubMed ID: 18301743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]